The decreased AML chemotaxis to this therapy-protective bone marrow microenvironment can allow for the release of leukemia cells and lead to the considerable therapeutic efficacy observed with DJ4 in murine studies. This evidence concerns the gene DNAJB6 and acute myeloid leukemia.